Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens.


Journal

Diabetes technology & therapeutics
ISSN: 1557-8593
Titre abrégé: Diabetes Technol Ther
Pays: United States
ID NLM: 100889084

Informations de publication

Date de publication:
17 May 2024
Historique:
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: aheadofprint

Résumé

Connected insulin pens capture data on insulin dosing/timing and can integrate with continuous glucose monitoring (CGM) devices with essential insulin and glucose metrics into a single platform. Standardization of connected insulin pen reports is desirable to enhance clinical utility with a single report. An international expert panel was convened to develop a standardized connected insulin pen report incorporating insulin and glucose metrics into a single, clinically useful report. An extensive literature review and identification of examples of current connected insulin pen reports was performed serving as the basis for creation of a draft of a standardized connected insulin pen report. The expert panel participated in three virtual standardization meetings and online surveys. The AGP Report: Connected Insulin Pen brings all clinically relevant CGM-derived glucose and connected insulin pen metrics into a single simplified two-page report. The first page contains the time in ranges bar, summary of key insulin and glucose metrics, the ambulatory glucose profile (AGP) curve, and detailed basal (long-acting) insulin assessment. The second page contains the bolus (mealtime and correction) insulin assessment periods with information on meal timing, insulin-to-carbohydrate ratio (ICR), average bolus insulin dose and number of days with bolus doses recorded. The report's second page contains daily glucose profiles with an overlay of the timing and amount of basal and bolus insulin administered. The AGP Report: Connected Insulin Pen is a standardized clinically useful report that should be considered by companies developing connected pen technology as part of their system reporting/output.

Sections du résumé

BACKGROUND BACKGROUND
Connected insulin pens capture data on insulin dosing/timing and can integrate with continuous glucose monitoring (CGM) devices with essential insulin and glucose metrics into a single platform. Standardization of connected insulin pen reports is desirable to enhance clinical utility with a single report.
METHODS METHODS
An international expert panel was convened to develop a standardized connected insulin pen report incorporating insulin and glucose metrics into a single, clinically useful report. An extensive literature review and identification of examples of current connected insulin pen reports was performed serving as the basis for creation of a draft of a standardized connected insulin pen report. The expert panel participated in three virtual standardization meetings and online surveys.
RESULTS RESULTS
The AGP Report: Connected Insulin Pen brings all clinically relevant CGM-derived glucose and connected insulin pen metrics into a single simplified two-page report. The first page contains the time in ranges bar, summary of key insulin and glucose metrics, the ambulatory glucose profile (AGP) curve, and detailed basal (long-acting) insulin assessment. The second page contains the bolus (mealtime and correction) insulin assessment periods with information on meal timing, insulin-to-carbohydrate ratio (ICR), average bolus insulin dose and number of days with bolus doses recorded. The report's second page contains daily glucose profiles with an overlay of the timing and amount of basal and bolus insulin administered.
CONCLUSION CONCLUSIONS
The AGP Report: Connected Insulin Pen is a standardized clinically useful report that should be considered by companies developing connected pen technology as part of their system reporting/output.

Identifiants

pubmed: 38758213
doi: 10.1089/dia.2024.0107
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Gregg D Simonson (GD)

HealthPartners Institute, International Diabetes Center, Bloomington, Minnesota, United States; gregg.simonson@parknicollet.com.

Amy Criego (A)

Park Nicollet - International Diabetes Center, Pediatric Endocrinology, 3800 Park Nicollet Blvd, Minneapolis, Minnesota, United States, 55372; Amy.Criego@ParkNicollet.com.

Tadej Battelino (T)

University Children's Hospital, Ljubljana, Slovenia, Department of Endocrinology, Diabetes and Metabolism, Bohoriceva 20, Ljubljana, Slovenia, 1000.
Slovenia; tadej.battelino@mf.uni-lj.si.

Anders L Carlson (AL)

International Diabetes Center, 3800 Park Nicollet Blvd, Minneapolis, Minnesota, United States, 55416; Anders.L.Carlson@HealthPartners.Com.

Pratik Choudhary (P)

University of Leicester, Diabetes, Gwendoloen Road, Leicester, United Kingdom of Great Britain and Northern Ireland, LE5 4PW; pratik.choudhary@leicester.ac.uk.

Sylvia Franc (S)

Sud-Francilien Hospital, Department of Diabetes, 116 Bd Jean Jaures, Corbeil-Essonnes, France, 91100; sylvia.franc@free.fr.

Dana Gershenoff (D)

Tandem Diabetes Care Inc, San Diego, California, United States; DGershenoff@tandemdiabetes.com.

George Grunberger (G)

Grunberger Diabetes Institute , George Grunberger, 43494 Woodward Avenue, suite 208, Bloomfield Hills, Michigan, United States, 48302.
United States; grunberger@gdi-pc.com.

Irl B Hirsch (IB)

University of Washington, 750 Republican, Building F, 3rd Floor, 3rd Floor, Seattle, Washington, United States, 98109; ihirsch@uw.edu.

Diana Isaacs (D)

Cleveland Clinic, Endocrinology, 10685 Carnegie Ave, Cleveland, Ohio, United States, 44106.
Cleveland Clinic Diabetes Center; isaacsd@ccf.org.

Mary Johnson (M)

International Diabetes Center, Research, 3800 Park Nicollet Blvd, Minneapolis, Minnesota, United States, 55416; Mary.L.Johnson@ParkNicollet.com.

David Kerr (D)

Center for Health Systems Research Sutter Health, Sutter Health, Santa Barbara, California, United States, 93103; david.kerr@sutterhealth.org.

Davida Kruger (D)

Henry Ford Health System, Endocrinology and Diabetes,Bone and Mineral Disorders, 3031 West Grand Blvd, Suite 800, Detroit, Michigan, United States, 48202.
661 Washington RoadGrosse Pointe, Michigan, United States, 48230; dkruger1@hfhs.org.

Chantal Mathieu (C)

8. University Hospital of Leuven, Dept. Medicine, Leuven, Belgium; chantal.mathieu@uzleuven.be.

Thomas Martens (T)

International Diabetes Center at Park Nicollet, 3800 Park Nicollet Blvd, Minneapolis, Minnesota, United States, 55416.
Park Nicollet Clinic, Minneapolis, Minnesota, United States; thomas.martens@parknicollet.com.

Revital Nimri (R)

Schneider Children's Medical Center of Israel, Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Kaplan 14, Petah Tiqva, Petah Tikva, Israel, 49202; revitalnimri@gmail.com.

Sean Oser (S)

University of Colorado School of Medicine, Aurora, Colorado, United States; sean.oser@cuanschutz.edu.

Anne Peters (A)

University of Southern California, USC Keck School of Medicine, Clinical Diabetes Programs, 150 N. Robertson Blvd, suite 210, Los Angeles, California, United States, 90211.
United States; momofmax@mac.com.

Ruth S Weinstock (RS)

SUNY Upstate Medical University, Medicine, 750 East Adams Street, CWB 353, Syracuse, United States, 13210; weinstor@upstate.edu.

Eugene E Wright (EE)

Duke Southern Regional AHEC, Department of Medicine and Community and Family Medicine, 1601 Owen Drive, Fayetteville, North Carolina, United States, 28304; eewright51@gmail.com.

Carol H Wysham (CH)

Multicare/Rockwood Center for Diabetes and Endocrinology, ENDOCRINOLOGY, 400 EAST FIFTH AVENUE, Spokane, Washington, United States, 99202; chwysham@comcast.net.

Richard M Bergenstal (RM)

International Diabetes Center, 3800 Park Nicollet Blvd, Minneapolis , Minnesota, United States, 55416; richard.bergenstal@parknicollet.com.

Classifications MeSH